Abstract: PO0880
Progression of Coronary Artery Calcification in Unit vs. Nocturnal Haemodialysis Patients
Session Information
- Fluid, Electrolytes, and Clinical Events with Dialysis: Getting to the "Heart" of the Matter
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Brown, Karen E., Morriston Hospital, Swansea, Wales, United Kingdom
- Bucknall, Thomas, Morriston Hospital, Swansea, Wales, United Kingdom
- Greene, Giles, Public Health Wales, Cardiff, Cardiff, United Kingdom
- Jefferies, Helen, Cardiff and Vale University Health Board, Cardiff, Cardiff, United Kingdom
- Mikhail, Ashraf I., Morriston Hospital, Swansea, Wales, United Kingdom
- Prior, Sarah L., Swansea University, Swansea, West Glamorgan, United Kingdom
- Stephens, Jeffrey W., Swansea University, Swansea, West Glamorgan, United Kingdom
- Obaid, Daniel R., Morriston Hospital, Swansea, Wales, United Kingdom
Background
CT coronary artery calcium (CAC) predicts future cardiac events. Inflammation and deranged bone mineralisation may contribute to atherogenesis and arterial calcification. We compared progression of CAC in unit and nocturnal haemodialysis patients.
Methods
Patients commencing unit haemodialysis (UHD=7) and nocturnal haemodialysis (NHD=10) were prospectively enrolled. CAC scores (Agatson) were obtained at 0 and 12 months. Inflammatory (hsCRP, IL-18, hepcidin) and bone mineralisation (PO4-, Ca2+, PTH) biomarkers were obtained at 0, 3 and 12 months.
Results
Groups were well matched for age, gender, aetiology of ESRD and cardiovascular risk factors. Average baseline CAC scores were similar between UHD and NHD but significant progression occurred only in UHD (Figure). The relative increase in CAC score was significantly higher for UHD (71.2%) than NHD (6.7%), p=0.04.
Over the study there were no significant changes in markers of bone mineralisation or inflammation for either group except patients undergoing NHD had a significant reduction in IL-18 (117pg/ml ± 59 to 75pg/ml ± 30, p=0.04).
Significant CAC progression (increase in CAC >20AU and >15% occurred in 4/7 (57%) of UHD patients compared with 2/10 (20%) undergoing NHD. CAC scores regressed in 1/7 (14%) of UHD patients and 4/10 (40%) of NHD. Hepcidin was the only biomarker associated with CAC progression, it was higher in the progressors: 370pg/mL [321– 398] than regressors: 243pg/ml [138–349], p=0.045 with increase in CAC score correlated to the level hepcidin r=0.51.
Conclusion
Extended hours NHD significantly decreased progression of CAC compared with UHD. Progression appeared to be more dependent on levels of inflammation than deranged bone mineralisation with hepcidin the best predictor of CAC progression, but larger scale studies are required.
Funding
- Private Foundation Support